Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 2Carcinoma, Renal Cell 2Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Neoplasm Metastasis 1Kidney Neoplasms 1Diarrhea 1Colitis 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Docetaxel 35pembrolizumab 32Nivolumab 27enzalutamide 20Prednisone 20Sunitinib 16Cyclophosphamide 16aldesleukin 14Zoledronic Acid 13Interleukin-2 13Gemcitabine 13Bevacizumab 13Specimen Handling 12Ipilimumab 12Radiosurgery 11Everolimus 11Androgen Antagonists 11Abiraterone Acetate 11fludarabine 10Sorafenib 10Radiotherapy 10Paclitaxel 10Magnetic Resonance Spectroscopy 10pazopanib 9abiraterone 9Doxorubicin 8Carboplatin 8Biopsy 8avelumab 7temsirolimus 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Fecal Microbiota Transplantation × Genitourinary × Clear all
NCT04116775 2022-06-23

Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.

Portland VA Medical Center

Phase 2 Unknown
32 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡